Icagen, Inc.'s Asthma Drug Meets Main Goal in Mid-Stage Study

Reuters -- Icagen Inc said its experimental treatment for allergic asthma met the main goal of reducing asthmatic response to inhaled allergen in a mid-stage trial, sending its shares soaring as much as 65 percent.